, Tracking Stock Market Picks
Enter Symbol:

up 127.49 %

HALOZYME THERAPEUTIC (HALO) rated Overweight with price target $27 by Barclays

Posted on: Tuesday,  Sep 22, 2015  1:25 PM ET by Barclays

Barclays rated Overweight HALOZYME THERAPEUTIC (NASDAQ: HALO) on 09/22/2015. Previously Barclays rated Overweight HALOZYME THERAPEUTIC (NASDAQ: HALO) on 09/24/2012., when
the stock price was $7.93. Since then, HALOZYME THERAPEUTIC has gained 127.49% as of 08/27/2015's recent price of $18.04.
If you would have followed the previous Barclays's recommendation on HALO, you would have gained 127.49% of your investment in 1067 days.

Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (Matrix) for the endocrinology, oncology, dermatology and drug delivery markets The Company's products are based on the property covering the family of human enzymes known as hyaluronidases. The Company has two marketed products: HYLENEX, a product used as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids, and Cumulase, a product used for in vitro fertilization (IVF). The Company has partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. (Roche), to apply Enhanze Technology to Roche?s biological therapeutic compounds for up to 13 targets, and with Baxter Healthcare Corporation (Baxter), to apply Enhanze Technology to Baxter?s biological therapeutic compound, GAMMAGARD LIQUID.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/22/2015 1:25 PM Buy
as of 8/27/2015
1 Week down  -14.58 %
1 Month down  -17.32 %
3 Months up  10.60 %
1 YTD up  20.34 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/10/2014 1:25 PM Buy
15.94 15.00
11/11/2013 2:25 PM Buy
13.24 12.00
8/2/2013 1:25 PM Buy
7.03 8.00
9/24/2012 1:25 PM Buy
7.93 10.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy